Intra-Cellular Therapies, Inc. (ITCI)
- Previous Close
67.00 - Open
66.97 - Bid 65.33 x 100
- Ask 65.73 x 100
- Day's Range
65.45 - 67.23 - 52 Week Range
45.50 - 84.89 - Volume
696,343 - Avg. Volume
977,998 - Market Cap (intraday)
6.921B - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.16 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
91.64
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
www.intracellulartherapies.com610
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ITCI
Performance Overview: ITCI
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ITCI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ITCI
Valuation Measures
Market Cap
6.92B
Enterprise Value
6.46B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.32
Price/Book (mrq)
11.54
Enterprise Value/Revenue
12.61
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-21.57%
Return on Assets (ttm)
-11.23%
Return on Equity (ttm)
-18.07%
Revenue (ttm)
513.93M
Net Income Avi to Common (ttm)
-110.87M
Diluted EPS (ttm)
-1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
475.62M
Total Debt/Equity (mrq)
2.73%
Levered Free Cash Flow (ttm)
-18.29M
Research Analysis: ITCI
Company Insights: ITCI
ITCI does not have Company Insights